Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Arena Pharmaceuticals (Nasdaq: ARNA) announced the granting of inducement stock options and restricted stock units (RSUs) to 20 new employees. The stock options allow the purchase of 33,340 shares at an exercise price of $59.09, the stock's closing price on September 15, 2021. The options have a seven-year term and vest over four years. RSUs, totaling 15,655, will vest similarly over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to support Arena's mission of delivering essential medicines to patients.

Positive

• Granting of 33,340 stock options may incentivize new employees and help attract talent.
• Inducement RSUs of 15,655 shares align employee interests with company performance.

Negative

• None.

PARK CITY, Utah--(BUSINESS WIRE)-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 20 new employees inducement stock options to purchase an aggregate of 33,340 shares of its common stock and 15,655 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of September 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement stock options are non-qualified stock options, have a seven-year term, have an exercise price of $59.09 per share, the closing price of Arena's common stock on the grant date, and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in substantially equal monthly installments over the following 36 months, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement RSUs vest over four years, with 25% of the shares vesting on the first designated quarterly vesting date on or following the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in 12 substantially equal quarterly installments occurring on the following 12 quarterly vesting dates, subject to the new employee's continued service with Arena through the applicable vesting dates. The inducement stock options and inducement RSUs are subject to the terms and conditions of Arena's Amended and Restated 2021 Long-Term Incentive Plan.

About Arena Pharmaceuticals

ARENA Pharmaceuticals is a team with a singular purpose – deliver important medicines to patients.

In a rapidly changing global market, we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to get medicines to patients, and relentlessly execute until it’s done.

ARENA - Care More. Act Differently.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's purpose, work, understanding, ideas, and execution. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005453/en/

Corporate Contacts:

Patrick Malloy

Arena Pharmaceuticals, Inc.

Vice President, Investor Relations & Corporate Communications

pmalloy@arenapharm.com

847.987.4878

Source: Arena Pharmaceuticals, Inc.

FAQ

What stock options were granted by Arena Pharmaceuticals on September 15, 2021?

Arena Pharmaceuticals granted inducement stock options to purchase 33,340 shares at an exercise price of $59.09.

How many restricted stock units were issued by Arena Pharmaceuticals?

Arena Pharmaceuticals issued 15,655 inducement restricted stock units (RSUs) to new employees.

What is the vesting schedule for the stock options and RSUs granted by Arena Pharmaceuticals?

The stock options vest over four years, with 25% after one year and the rest in monthly installments. The RSUs vest with 25% after one year and the remaining 75% in quarterly installments.

What is the purpose of granting stock options and RSUs to new employees at Arena Pharmaceuticals?

The grants serve as inducements to attract and retain talent essential for Arena's mission.

Under which Nasdaq rule were the stock options and RSUs granted by Arena Pharmaceuticals?

The stock options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).